Clinical Trials
30 trialsDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
Jiangmen Central Hospital
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd.
Aurora004
Shanghai Pulmonary Hospital, Shanghai, China
Aurora 005
Shanghai Pulmonary Hospital, Shanghai, China
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
The Second Affiliated Hospital of Dalian Medical University
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
Fudan University
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Using Tumor Models to Determine Treatments
University Health Network, Toronto
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
MEPENDAX
Assistance Publique Hopitaux De Marseille
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NeoSCLC-001
Beijing Chest Hospital, Capital Medical University
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
PANDORA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
Affiliated Cancer Hospital & Institute of Guangzhou Medical University